Universidad Nacional de Colombia

3 in Phase 3

Quick facts

Phase 3 pipeline

Fluconazole and Secnidazole · Infectious Disease
Fluconazole and secnidazole is a combination antifungal and antiprotozoal agent that inhibits fungal ergosterol synthesis and disrupts protozoal DNA, respectively.
Ivermectin 0.1% Metronidazole 1% · Infectious Disease / Dermatology
This combination product uses ivermectin to paralyze parasites and metronidazole to disrupt microbial DNA, targeting parasitic and anaerobic bacterial infections.
Standard care Hyaluronic acid eye drops · Ophthalmology
Hyaluronic acid eye drops work by providing lubrication to the eyes, helping to relieve dryness and irritation.

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Universidad Nacional de Colombia

What is Universidad Nacional de Colombia's pipeline?

Universidad Nacional de Colombia has 3 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include Fluconazole and Secnidazole, Ivermectin 0.1% Metronidazole 1%, Standard care Hyaluronic acid eye drops.

Sector hub: All tracked pharma companies